PMID- 38162801
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240103
IS  - 1178-7007 (Print)
IS  - 1178-7007 (Electronic)
IS  - 1178-7007 (Linking)
VI  - 16
DP  - 2023
TI  - Effect of Chiglitazar and Sitagliptin on Bone Mineral Density and Body 
      Composition in Untreated Patients with Type 2 Diabetes.
PG  - 4205-4214
LID - 10.2147/DMSO.S439479 [doi]
AB  - AIM: To evaluate the changes in bone mineral density (BMD) and body composition 
      in untreated patients with type 2 diabetes mellitus (T2DM) before and after 
      chiglitazar or sitagliptin treatment. METHODS: A total of 81 patients with T2DM 
      were randomly divided to receive chiglitazar or sitagliptin treatment for 24 
      weeks (54 in the chiglitazar group and 27 in the sitagliptin group). We measured 
      the spine lumbar BMD, hip BMD, fat mass (FM), fat-free mass (FFM), percent body 
      fat (%BF), android FM, gynoid FM and skeleton muscle mass (SMM) using dual-energy 
      X-ray absorptiometry (DEXA) and examined serum adiponectin (ADP) levels at 
      baseline and the end of the study. RESULTS: There were no significant changes in 
      the BMD of the L2-4, femoral neck, trochanter or total hip as well as in the BMC 
      after 24 weeks of treatment with chiglitazar or sitagliptin. After chiglitazar 
      administration, the FM, gynoid FM and gynoid to total FM ratio were higher, while 
      the android to total FM ratio and the android to gynoid FM ratio (AOI) were 
      significantly lower. Sitagliptin intervention did not result in statistically 
      significant differences in total fat loss, but it did cause significant decreases 
      in %BF and AOI as well as increases in the FFM, gynoid to total FM ratio and SMM. 
      The ADP levels had significantly negative associations with AOI in all eligible 
      patients. CONCLUSION: The chiglitazar had no deleterious effects on BMD and 
      resulted in body fat redistribution in untreated patients with T2DM. TRIAL 
      REGISTRATION: The trial is registered at ClinicalTrials.gov (CT.gov identifier: 
      NCT02173457).
CI  - (c) 2023 Wang et al.
FAU - Wang, Yuming
AU  - Wang Y
AD  - Department of Geriatrics, Nanjing Drum Tower Hospital, the Affiliated Hospital of 
      Nanjing University Medical School, Nanjing, 210008, People's Republic of China.
AD  - Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, 
      Nanjing, 210012, People's Republic of China.
FAU - Zhou, Yunting
AU  - Zhou Y
AD  - Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, 
      Nanjing, 210012, People's Republic of China.
FAU - Zhou, Xiao
AU  - Zhou X
AD  - Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, 
      Nanjing, 210012, People's Republic of China.
FAU - Su, Xiaofei
AU  - Su X
AD  - Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, 
      Nanjing, 210012, People's Republic of China.
FAU - Xu, Xiaohua
AU  - Xu X
AD  - Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, 
      Nanjing, 210012, People's Republic of China.
FAU - Li, Huiqin
AU  - Li H
AUID- ORCID: 0000-0002-6319-1196
AD  - Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, 
      Nanjing, 210012, People's Republic of China.
FAU - Ma, Jianhua
AU  - Ma J
AUID- ORCID: 0000-0001-9383-2559
AD  - Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, 
      Nanjing, 210012, People's Republic of China.
LA  - eng
SI  - ClinicalTrials.gov/NCT02173457
PT  - Journal Article
DEP - 20231227
PL  - New Zealand
TA  - Diabetes Metab Syndr Obes
JT  - Diabetes, metabolic syndrome and obesity : targets and therapy
JID - 101515585
PMC - PMC10757783
OTO - NOTNLM
OT  - PPAR
OT  - body composition
OT  - bone mineral density
OT  - chiglitazar
OT  - type 2 diabetes mellitus
COIS- The authors report no conflicts of interest in this work.
EDAT- 2024/01/02 11:44
MHDA- 2024/01/02 11:45
PMCR- 2023/12/27
CRDT- 2024/01/01 04:29
PHST- 2023/10/09 00:00 [received]
PHST- 2023/12/14 00:00 [accepted]
PHST- 2024/01/02 11:45 [medline]
PHST- 2024/01/02 11:44 [pubmed]
PHST- 2024/01/01 04:29 [entrez]
PHST- 2023/12/27 00:00 [pmc-release]
AID - 439479 [pii]
AID - 10.2147/DMSO.S439479 [doi]
PST - epublish
SO  - Diabetes Metab Syndr Obes. 2023 Dec 27;16:4205-4214. doi: 10.2147/DMSO.S439479. 
      eCollection 2023.